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Abstract
Human African trypanosomiasis (HAT) is a disease caused by infection with the parasite
Trypanosoma brucei gambiense or T. b. rhodesiense. It is transmitted to humans via the
tsetse fly. Approximately 70 million people worldwide were at risk of infection in 1995, and
approximately 20,000 people across Africa are infected with HAT. The objective of this re-
view was to identify existing economic evaluations in order to summarise cost-effective in-
terventions to reduce, control, or eliminate the burden of HAT. The studies included in the
review were compared and critically appraised in order to determine if there were existing
standardised methods that could be used for economic evaluation of HAT interventions or
if innovative methodological approaches are warranted. A search strategy was developed
using keywords and was implemented in January 2014 in several databases. The search
returned a total of 2,283 articles. After two levels of screening, a total of seven economic
evaluations were included and underwent critical appraisal using the Scottish Intercolle-
giate Guidelines Network (SIGN) Methodology Checklist 6: Economic Evaluations. Results
from the existing studies focused on the cost-effectiveness of interventions for the control
and reduction of disease transmission. Modelling was a common method to forecast long-
term results, and publications focused on interventions by category, such as case detec-
tion, diagnostics, drug treatments, and vector control. Most interventions were considered
cost-effective based on the thresholds described; however, the current treatment, nifurto-
mix-eflornithine combination therapy (NECT), has not been evaluated for cost-effective-
ness, and considerations for cost-effective strategies for elimination have yet to be
completed. Overall, the current evidence highlights the main components that play a role in
control; however, economic evaluations of HAT elimination strategies are needed to assist
national decision makers, stakeholders, and key funders. These analyses would be of use,
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as HAT is currently being prioritized as a neglected tropical disease (NTD) to reach elimi-
nation by 2020.
Background
Human African trypanosomiasis (HAT) is a disease caused by infection with the parasite Try-
panosoma brucei gambiense or T. b. rhodesiense and is transmitted to humans via the tsetse fly.
Approximately 70 million people worldwide were at risk of infection in 1995 [1], and although
7,216 cases were reported in 2012 [2], it is estimated that approximately 20,000 people across
Africa are infected with HAT [2]. According to the Global Burden of Disease, recent estimates
of years lived with disability (YLDs) for HAT annually range from 2,000 to 25,000 [3]. There
are approximately 30 African countries affected by this disease, and it has been identified by
the World Health Organization (WHO) as a neglected tropical disease (NTD) [4].
WHO describes the disease as a neurological breakdown that is caused by the trypanosome
parasite in the brain, which eventually leads to a coma or death if a patient is not treated [5].
Patients are identified by self-reporting to health care centres (referred to as “passive case de-
tection”), while active screening by trained professionals in mobile teams continues in high-
and moderate-transmission areas. Active screening campaigns are carried out in remote vil-
lages, and a series of tests are used for the diagnosis of the disease. The current diagnostic algo-
rithms for HAT include the card agglutination test for trypanosomiasis (CATT) followed by
full blood assays to identify the parasite microscopically. Lumbar puncture with parasitological
confirmation is then used for staging of the disease. Patients that are diagnosed with HAT are
then referred to HAT treatment centres. Limited active screening is done for T. b. rhodesiense
because there is no serological test available to facilitate easy identification. Hence, most T. b.
rhodesiense cases are detected by clinical signs and symptoms. The subsequent diagnostic steps
are similar to T. b. gambiense in that parasite detection is done using chancre aspirate or blood,
and staging of the disease again uses cerebrospinal fluid obtained from lumbar puncture. The
treatments for T. b. gambiense and T. b. rhodesiense also differ. Treatment for T. b. gambiense
includes a 7-day intramuscular injection treatment of pentamidine for patients in stage 1 of the
disease that is generally well tolerated, with minor adverse events. Nifurtimox-eflornithine
combination therapy (NECT) is a 14-day in-hospital chemotherapy treatment that is required
for patients suffering from stage 2 of HAT. The adverse events commonly seen in patients
treated with NECT are considered to be mild to moderate in severity. For HAT T. b. rhode-
siense, the treatment for stage 1 includes weekly intravenous injections of suramin over the
course of 5 weeks [5]. Negative reactions to suramin coincide with the patient’s health status,
but overall, it is a well-tolerated treatment. Stage 2 treatment for T. b. rhodesiense is a 10-day
treatment of melarsoprol. Melarsoprol is the most toxic of the HAT treatments, leading to
encephalopathic syndrome in 5% to 18% of patients treated and often resulting in death. Vec-
tor control methods for prevention of HAT T. b. rhodesiense are commonly used, as the disease
is well-known to have an animal reservoir that contributes to transmission in both human and
animal populations [5]. In regards to HAT T. b. gambiense, historically, vector control has not
been suggested. However, evidence of an animal reservoir for T. b. gambiense has been dis-
cussed [6,7], and vector control was recently encouraged by WHO as an integrated strategy for
HAT [5].
The year scheduled for HAT elimination is 2020 [8], and as this deadline approaches, re-
search groups are currently developing new drug treatments and diagnostic tools [9–11] for
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HAT. Additionally, experts in vector control methods are also seeking interventions that
would be more cost-effective and feasible for communities at risk for the disease. Even tradi-
tional teams that have gone out via trucks are now being reconsidered in combination with
newer drug treatments using motorbike teams. Although some screening programs include a
component of community sensitization, community involvement within control and elimina-
tion campaigns and knowledge of how this “disease awareness” is translated into behavioural
changes and attitudes within affected populations need to be considered. There is now a need
to evaluate not only the possibility of control and elimination for HAT but also how these new
interventions and approaches may contribute to the grand scheme of such endeavours.
WHO has provided recommendations to improve certain factors likely to achieve elimina-
tion [2], and decision makers have also committed to funding the elimination of the disease
[12]; yet, a clear path to the achievement of this goal is not available, nor is it clear what the
most efficient pathway towards elimination would be. In addition, thus far there has been no
synthesis of the current costs and effectiveness of all strategies that could intervene in the trans-
mission of the disease. The objective of this review was to identify existing economic evalua-
tions in order to summarise cost-effective interventions to reduce, control, or eliminate the
burden of HAT. The studies included in the review were compared and critically appraised in
order to determine if there were standardised methods that could be used for economic evalua-
tions of HAT interventions or if innovative methodological approaches are warranted.
Methods
Literature Search Strategy
A literature search was conducted via the OvidSp interface on January 22, 2014 using keywords
for HAT specific to the Medical Subject Headings (MeSH) terms required for Medical Litera-
ture Analysis and Retrieval System Online (MEDLINE) and Embase databases. An economic
filter developed by Scottish Intercollegiate Guidelines Network (SIGN) was also applied. (Refer
to S1 Supporting Information) The Journal Storage (JSTOR) database was also searched using
the following key words: African trypanosomiasis OR trypanosom& OR “sleeping sickness”
AND cost& AND economics. In addition, the following keywords were also searched in the
Database of Abstracts of Reviews of Effects (DARE), National Health Service Economic Evalu-
ation Database Health Technology Assessment (NHSEED HTA), and Cochrane databases:
“African” AND “Trypanosomiasis” OR “sleeping sickness”. All citations were downloaded into
Mendeley, where duplicates were identified and removed.
Literature Screening & Inclusion/Exclusion Criteria
Screening of the articles was done in two stages. At the first level, all titles and abstracts were
screened. Articles that were considered potentially relevant were then assessed at the second
level, in which the full text was read. After reading the full text, articles that still met the inclu-
sion criteria were considered. A full description of the inclusion and exclusion criteria is avail-
able in S2 Supporting Information. Data were screened on both levels according to the outline
of population-intervention-comparators-outcomes-setting (PICOS) criteria, in which the pop-
ulation pertained to humans. Evaluations regarding strains of both HAT T. b. gambiense and
T. b. rhodesiense were reviewed, although outcomes only pertaining to humans impacted by
the disease were taken into consideration (no animal implications). Interventions (I) and com-
parators (C) included any intervention that could lead to prevention or reduction of disease in
human populations (including vector control). The outcomes (O) that were considered for re-
view were costs, consequences (life-years saved [LYS], disability-adjusted life years [DALYs],
etc.), and the incremental cost-effectiveness ratio (ICER), while the setting (S) included any
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African country. For the purpose of this analysis, an economic evaluation was defined by the
Drummond et al. definition of a “full economic evaluation,” and therefore, both costs and con-
sequences of two or more alternatives had to be present in the analyses evaluated [13]. In cases
in which an incremental analysis was not performed, articles were not excluded. Instead, if
there was sufficient information in the publication to calculate the ICER, it was calculated dur-
ing the review process. If there was insufficient information to calculate the ICER, it was noted
in the critical appraisal that an incremental analysis was not present. No time constraints were
added to the search.
Quality Assessment and Critical Appraisal
The quality of the included studies was assessed using the SIGNMethodology Checklist 6: Eco-
nomic Evaluations Version 3.0 [14], which was composed of two parts. The first portion con-
tained questions regarding the internal and external validity of the publication. Items in the
sections were assessed using answers of “Yes,” “No,” or “Can’t say.” The second portion of the
checklist addressed the reviewers overall assessment of the study and also provided the review-
er with an area to judge if the article was “unacceptable,” “acceptable,” or of “high quality.”
Studies that received a “Yes” on 65% or more of the questions in Section 1 were considered ac-
ceptable to the authors.
Results
Literature Search Results
The NHSEED, JSTOR, MEDLINE, and Embase searches yielded a total of seven articles, 1,000
articles, 595 articles, and 673 articles, respectively. An additional eight articles from the grey lit-
erature, reference lists, and referrals from subject matter experts were also included. There
were a total of 2,283 studies found, and after the removal of duplicates, 2,095 were chosen for
primary screening (title and abstracts). A total of 41 publications were then selected for full-
text screening. Thirty-four studies were excluded after full-text review, and reasons for exclu-
sion were recorded. (Refer to Table 1.) Seven full texts [15–21] were included for full critical ap-
praisal and data abstraction for analysis. (Refer to Fig. 1.)
Quality Assessment and Critical Appraisal
The quality scores for the seven included studies [15–21] displayed in Table 2 (SIGNMethod-
ology Checklist 6: Economic Evaluations) demonstrated that on average 81% (67%–89%) of
the items stipulated by the SIGN checklist were addressed. Economic theory suggests that indi-
viduals have a time preference in regards to gains, and hence, costs and outcomes in the future
are less valuable than those in the present [22]. This concept is referred to as “discounting” and
is standard methodology in economic evaluation; however, five out the seven studies in this re-
view did not address it [16–19,21]. Each publication considered the cost and consequence com-
pared to more than one intervention for HAT; however, three of the publications [15,17,18]
did not include an incremental analysis to examine the marginal benefit of adopting one inter-
vention compared to the next best option. A single study [19] did not have a clear objective,
and Shaw’s study did not justify the study design or clearly describe the cost sources [15]. All
but one study [20] completed a sensitivity analysis in addition to the base results. All studies
discussed the economic importance of the question and had outcomes that could be relevant
for decision makers. Overall, all studies were judged to be “acceptable” for this review.
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Characteristics of Included Economic Evaluations
Each of the seven included publications had varying characteristics, as summarised in Table 3.
The first publication of a full economic evaluation for HAT identified was completed in 1989
by Alexandra Shaw [15], with the next publication coming in 1995 [16]. The remaining five
Table 1. Characteristics of excluded studies at second-level screening.
Author Year Reason excluded
Abila [44] 2007 Cost-effectiveness but interventions and outcomes related to fly population only
Brandl [45] 1988 Costs only, no effectiveness
Brightwell [46] 1991 Cost per trap discussed, paper related to effectiveness of trap as opposed to
cost-effectiveness of relative comparators
Checchi [47] 2011 Screening algorithms (sensitivity/specificity outcomes only)
Esterhuizen
[48]
2011 No actual costs discussed, just effectiveness of fly traps
Etchegorry [49] 2001 Costs only, no effectiveness
Fèvre [50] 2008 DALYs and burden of illness
Fèvre [51] 2008 DALYs and burden of illness
Gouteux [52] 1987 Costs only, no effectiveness
Jordan [53] 1961 Discussion only of economic importance, not actual economic analysis
Kamuanga [54] 2001 CBA using CV but outcomes based on preference for animals and not HAT
Laveissière [55] 1990 Costs only, no effectiveness
Laveissière [34] 1998 Costs only, no effectiveness
Leygues [30] 1989 Socioeconomic outcomes, not cost-effectiveness
Lutumba [56] 2005 Costs only, no effectiveness
Lutumba [57] 2006 Costs only, no effectiveness
Matemba [58] 2010 Costs and DALYs for one area, not comparative analysis
McDermott [59] 2001 Modelling of vector control only, not actual economic analysis
Mitashi [60] 2012 Screening algorithms (sensitivity/specificity outcomes only)
Mugasa [61] 2012 Screening algorithms (sensitivity/ specificity outcomes only)
Okoth [62] 1991 Costs only, no effectiveness
Putt [63] 1988 Costs only, no effectiveness
Ruiz-Postigo
[64]
2001 Costs only, no effectiveness
Shaw [65] 2004 Chapter 20 about the economics of trypanosomiasis; summary of research but
no formal incremental CEA
Shaw [66] 2006 Prevention and outcomes focussed on livestock, not human outcomes
Shaw [67] 2007 Costs only, no effectiveness
Shaw [68] 2009 Costs only, no effectiveness
Shaw [69] 2013 Costs only, no effectiveness
Simarro [70] 2011 Costs only, no effectiveness
Simarro [71] 2012 Costs only, no effectiveness
Trowbridge [72] 2000 Abstract only; did not mention any costs, just DALYs
Vale [73] 2005 Cost and benefits but related to vector control interventions related to fly
populations only
Vos [3] 2012 DALYs and burden of illness
WHO Report
[74]
1998 Costs only, no effectiveness
Abbreviations: CBA, cost-benefit analysis; CV, contingent valuation.
doi:10.1371/journal.pntd.0003397.t001
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publications were published from 2005 to 2008 [17–21]. The evaluations covered four African
countries: Democratic Republic of the Congo (DRC), Uganda, Côte d’Ivoire, and Angola. Most
(3/7) evaluations (n = 3) came from DRC [18–20], with one study from Côte d’Ivoire [15], one
study from Uganda [16], one study from Angola [21], and finally one study that included an
analysis from both Uganda and Côte d’Ivoire [17]. Economic evaluations concerning HAT in
human populations looked almost exclusively at the disease T. b. gambiense (71%), although in
two instances the disease strain was not specified explicitly [15,21]. A total of four economic
evaluations [15,18,19,21] were considered cost-effectiveness analyses (CEA) in which the cost
for a desired effect or consequence (e.g., lives saved, years of infection avoided, etc.) was mea-
sured. Two studies [16,20] included both a CEA and cost utility analysis (CUA) in which the
utility was measured in DALYs. One study exclusively completed a CUA in which cost per
DALY averted was measured as the main outcome [17]. Overall, there was only one publication
that was found in an “economic” journal, as the remaining articles were published in journals
Fig 1. Preferred reporting items for systematic reviews andmeta-analyses (PRISMA) diagram. JSTOR, Journal Storage; MEDLINE, Medical Literature
Analysis and Retrieval SystemOnline; NHSEED, National Health Service Economic Evaluation Database. 1000*: Although 1,490 articles were found using
JSTOR, only 1,000 articles were accessible due to limitations of the JSTOR database.
doi:10.1371/journal.pntd.0003397.g001
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pertaining to tropical medicine and infectious diseases. Funding for the research was often not
mentioned. However, WHO was referred to as a means of support in two publications [16,18],
and support from the Belgian Directorate General for Development Cooperation was also
mentioned [18].
Interventions
The majority (5/7) of the publications evaluated interventions that included case detection and di-
agnosis, while two of the articles evaluated treatment interventions of melarsoprol and eflornithine
(difluoromethlyornithine [DFMO]) for stage 2, as the treatment for stage 1 was always considered
to be pentamidine [16,21]. Two publications by Lutumba [18,19] looked exclusively at sensitivity
and specificity of diagnostic algorithms and staging algorithms, while one study also looked at the
differences between treatment and vector control interventions in addition to case detection and
diagnosis [15]. The study by Shaw in 1989 was the only publication that included a comparative
economic analysis for vector control as an intervention to control HAT in a human population.
Table 2. Critical appraisal (Scottish Intercollegiate Guidelines Network (SIGN) Methodology Checklist 6: Economic Evaluations).
Author Question Shaw [15] Politi [16] Shaw [17] Lutumba[18] Lutumba [20] Lutumba [19] Robays [21]
Year 1989 1995 2001 2005 2007 2007 2008
SECTION 1. Internal Validity
1.1 The study addresses an appropriate
and clearly focused question
Yes Yes Yes Yes No Yes Yes
1.2 The economic importance of the
question is clear
Yes Yes Yes Yes Yes Yes Yes
1.3 The choice of study design is justified Can’t say Yes Yes Yes Yes Yes Yes
1.4 All costs that are relevant from the
viewpoint of the study are included and
are measured and valued appropriately
No Yes Yes Yes Yes Yes Yes
1.5 The outcome measures used to
answer the study question are relevant
to that purpose and are measured and
valued appropriately
Yes Yes Yes Yes Yes Yes Yes
1.6 If discounting of future costs and
outcomes is necessary, it been
performed correctly
Yes NA No NA Yes NA Can’t say
1.7 Assumptions are made explicit and a
sensitivity analysis performed
Yes Yes Yes Yes No Yes Yes
1.8 The decision rule is made explicit and
comparisons are made on the basis of
incremental analysis
No Yes No No* Yes Yes Yes
1.9 The results provide information of
relevance to policy makers
Yes Yes Yes Yes Yes Yes Yes
Total
fulfilment
6 8 7 7 7 8 8
67% 89% 78% 78% 78% 89% 89%
SECTION 2. Overall Assessment of the Study
2.1 How well was the study conducted? Acceptable Acceptable Acceptable Acceptable Acceptable Acceptable Acceptable
2.2 Are the results of this study directly
applicable to the patient group targeted
by this guideline?
Yes Yes Yes Yes Yes Yes Yes
*Base case analysis was not incremental, but sensitivity analysis had an incremental analysis
doi:10.1371/journal.pntd.0003397.t002
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Economic Evaluation Description
Key insights regarding the details of the included economic evaluations are described below
and also summarised in Table 4.
Methods and Software
Six of the seven included studies used modelling to measure outcomes for the economic evalua-
tion. Only one study completed an economic evaluation alongside a clinical trial. The most
common form of modelling was decision tree modelling; the structure of the remaining models
was not described in detail although they were all described as being implemented with spread-
sheets. For decision tree models, TreeAge software (TreeAge Software, Williamstown, Massa-
chusetts, United States) was used for three of four studies [18,19,21], and one publication did
not mention which software was used. The two spreadsheet models that were reviewed [15,17]
used Super-Calc 4 (Sorcim, Silicon Valley, California, US) and Microsoft Excel (Microsoft
Table 3. Characteristics of included economic evaluations.
Author Shaw [15] Politi [16] Shaw [17] Lutumba[18] Lutumba [20] Lutumba [19] Robays [21]
Year 1989 1995 2001 2005 2007 2007 2008
Type of
Intervention
Case
Detection and
Diagnosis +
Treatment,
Vector
Control
Treatment Case Detection
and Diagnosis
Diagnosis Case Detection and
Diagnosis
Diagnosis Treatment
Country Côte D’Ivoire Uganda Uganda, Cote
D’Ívoire
DRC DRC DRC Angola
Disease Strain Not
mentioned
T. b. gambiense T. b. gambiense T. b. gambiense T. b. gambiense T. b. gambiense T. b. gambiense*
Type of
Economic
Evaluation
CEA CEA/CUA CUA CEA CEA/CUA CEA CEA
Journal Annales de la
Société belge
de médecine
tropicale
Health Economics Médicine
Tropicale
Tropical Medicine and
International Health
Emerging Infectious
Diseases
Emerging
Infectious
Diseases
Tropical Medicine
and International
Health
Funding Not
mentioned
Internship at WHO Not mentioned WHO (Organisation
mondiale de la Santé)
and bourse de doctorat
Direction Générale de la
Coopération au
Développement du
Royaume de Belgique
avec l’Institut de
Médecine Tropicale
Prince Leopold
Financed partly by
doctoral grant from
the Belgian
Directorate General
for Development
Cooperation by
WHO
None mentioned None
Additional
Institutional
Collaborators
Members at
WHO,
member from
Oxford
University;
VEERU
Departments in WHO:
Division of Intensified
Cooperation with
countries, Division of
Control of Tropical
Diseases and Special
Programme in Tropical
Disease Research;
Batelle MEDTAP,
London; anonymous
referees
TDR/WHO as
Institutional
collaborators
None National Program in
DRC
HAT experts None
Abbreviations: MEDTAP, Medical Technology Assessment and Policy; TDR, Tropical Disease Research; VEERU, Veterinary Epidemiology and
Economics Research Unit. *Inferred T. b. gambiense because of treatments being used.
doi:10.1371/journal.pntd.0003397.t003
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Corp., Redmond, Washington, US) software, while the economic evaluation alongside clinical
trial (EEACT) [20] relied on Microsoft Access (Microsoft Corp., Redmond, Washington, US),
Microsoft Excel (Microsoft Corp., Redmond, Washington, US), and Epi Info 2002 (Centers for
Disease Control and Prevention, Atlanta, Georgia, US).
Model Structure, Assumptions & Validation
A visual diagram of the model was provided for five of the six studies that included models
[16–19,21]. Although descriptions of the six models were available, no details of the assump-
tions or justification for the inputs used in the modelling were addressed in any of the included
literature. None of the articles reported completing an internal validation of the models, but
the authors of one article [19] did compare their outcomes to other literature in similar areas
for external validity.
Population, Setting, and Perspective
In one of the modelling studies, the number of patients modelled was not mentioned, while the
remaining studies included 690 to 1,000,000 hypothetical patients. The clinical trial included a
total of 57 patients from 47 households [20]. As mentioned previously, the populations were
based on four countries (DRC, Côte D’Ivoire, Angola, and Uganda), with different settings in-
cluding: rural communities, health centres, and a sleeping-sickness hospital ward.
In one case [15], the perspective of the analysis was not mentioned, but two articles ap-
proached the economic evaluation from a societal perspective [16,20], and the remaining four
articles used the provider perspective (e.g., a donor or national health service) [17–19,21].
Additional Inputs, Outcomes, and Features of Included Economic
Evaluations
Data sources for the economic evaluations came from clinical trials, primary data collection
from national programmes (e.g., Programme National de Lutte contre la Trypanosomiase Hu-
maine Africaine [PNTHLA], Médecins Sans Frontières [MSF], and National Sleeping Sickness
Programme Uganda), reports fromWHO, available literature, and from speaking with experts
in the arena of HAT. Prevalence values were not mentioned in two studies and ranged from
0.1% to 70% in the remaining literature.
All costs were evaluated in US dollars (USD} [15–18,20,21] except for one study by Lutumba
et al. [19] that estimated cost-effectiveness in euros. Three studies reported only one outcome,
while the remaining studies reported two outcomes in terms of cost per outcome. Cost per
DALY averted was reported in three studies, while cost per LYS was reported in four studies.
Cost per years of life lost (YLL), cost per patient/control case detected or patient cured, and cost
per infection prevented were also examples of cost-effectiveness reported in the literature re-
viewed. Shaw (1989) and Shaw and Catt and reported time horizons of 20 years and one year,
respectively [15,17]. Studies that used decision tree modelling did not report time horizons as
decision trees have no time-related component [16,18,19]. The two remaining studies did not
report a discrete time horizon for the analysis [20,21]. Two publications reported using discount
rates of 10% [15,21], while one publication reported using a discount rate of 3% [20]. The re-
maining publications did not mention any discounting [16–19], which was probably due to the
fact that decision trees were used and therefore had no time horizon that or the time span mod-
elled was one year or less. Two of the seven articles made explicit references to willingness-to-
pay (WTP) thresholds for the cost-effectiveness of HAT as US$25/DALY [16,17]. One article
mentioned that theWHO-CHOICE (CHOosing Interventions that are Cost-Effective) consid-
ered the gross domestic product (GDP) per capita of a country to be used as theWTP threshold
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for choosing between competing interventions [21,23]. The remaining publications [15,18–21]
made no reference to a WTP threshold for the economic analysis under evaluation.
Base Case and Sensitivity Analyses
A full description of the economic outcomes for each study is outline in Table 5. The results
from the sensitivity analyses conducted for the included publications are provided in Table 4.
A total of 5 studies [16,18–21] discussed cost-effectiveness results by calculating incremental
cost-effectiveness ratios (ICERs), which are summarised in Table 5. Lutumba and colleagues
published cost-effectiveness analyses of varying diagnostic algorithms for HAT [18,19]. Their
results in 2005 demonstrated that lymph node puncture (LNP) in addition to CATT was more
cost-effective ($20/LYS) relative to CATT alone or LNP alone [18]. In 2007, LNP followed by
capillary tube centrifugation (CTC) and mini-anion exchange centrifugation technique
(mAECT) (€76/LYS); LNP followed by thick blood film (TBF), CTC, and mAECT (€200/LYS);
and LNP followed by TBF, CTC, mAECT, and CATT titration (€2,618/LYS) were deemed
cost-effective relative to four other diagnostic algorithms. Although the strengths of these cost-
effective algorithms were noted, Lutumba and colleagues noted that some of these algorithms
may not be feasible to carry out in the field [19]. In regards to treatment regimens, Politi’s anal-
ysis [16] in 1995 demonstrated that based on a WTP of US$25/DALY, melarsoprol alone (ini-
tial treatment and relapses) was cost-effective at US$8/DALY (US$209/LYS) compared to no
treatment. Politi’s analysis also demonstrated that a treatment pathway of melarsoprol with
treatment relapses on Eflornithine (difluoro-methylornithine [DMFO]) (US$41/DALY and US
$1,033/LYS) or DMFO for both treatment and relapses (US$167/DALY and US$4,444/LYS)
would not have been considered cost-effective based on the aforementioned cost-effectiveness
threshold of US$25/DALY [16]. A more recent publication by Robays demonstrated that
DFMO was more cost-effective than melarsoprol (US$1,596/LYS and US$58/control case de-
tected) when donated drug costs were not included; the analysis of cost-effectiveness was based
onWHO-CHOICE’s suggestion that interventions at a cost of GDP per capita are very cost-ef-
fective and interventions at three times GDP per capita are cost-effective [24]. When donated
drug costs were included, Robays found that DFMO was more cost-effective than melarsoprol
at US$8,169/LYS and US$299/control case detected. Lutumba et al. [20] found that active
screening (case detection) in addition to treatment was more cost-effective than treatment
alone at $17/DALY averted and $301/control case detected or patient cured.
Two studies [15,17] did not report cost and effect results incrementally. Although Shaw et al.
[15,17] conducted several analyses exploring combinations of case detection, diagnostics, treat-
ment, and vector control, outcomes were not compared incrementally; consequently, ICERs
were not attained. They did calculate $/patient detected with varying prevalence for five strategies
and found that lower prevalence rates were associated with higher $/DALY and higher preva-
lence rates with lower $/DALY; these were based on average cost-effectiveness ratios, not ICERs.
All but one study included some form of one-way sensitivity analysis (OWSA). No studies
completed subgroup analyses or conducted probabilistic sensitivity analyses (PSA), and hence,
results were not presented using cost-effectiveness acceptability curves (CEAC). Additional
measures of uncertainty were not explored in the form of a value of information (VOI) analysis
in any of the reviewed publications.
Discussion
A review of previous evidence has demonstrated that there have been only a few economic
evaluations conducted to assess the cost-effectiveness of interventions to control HAT and re-
duce disease burden. From this evidence alone, it would prove difficult for decision makers to
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strategize on which interventions would be most cost-effective for elimination; however, the re-
sults do provide some insights into the key components of HAT disease control and how these
components could be translated into HAT elimination strategies, which could then be assessed
through economic evaluation.
Overall the strengths of this review are that it highlights the components that play a role in
disease control and reduction of transmission and emphasizes that these are the components
that should be incorporated into elimination strategies. Case detection, diagnosis, treatment, and
vector control are the four categories of interventions that have been considered thus far in the
Table 5. ICER results from economic evaluations.
Author, Year Type of Intervention Name of Intervention ICER Results
Cost/DALY
Averted
Cost/LYS Cost/YLL Averted Cost/Control
Case Detected
Shaw, 2001
[17]
Case detection and diagnosis 1. Systematic fixed postsurveillance
at rural health centres
NA NA NA NA
2. Filter paper sample (rural health
centres)
3. Filter paper sample (community
health workers)
4. Polyvalent mobile teams
5. Monovalent mobile teams
Lutumba,
2005 [18]
Diagnosis 1. CATT - 1. - - -
2. LNP 2. dominated by 1
3. LNP + CATT 3. $20*
Lutumba,
2007 [19]
Diagnosis 1. LNP-FBE-TBF - 1. - - -
2. LNP-CTC 2. ED by 4
3. LNP-CATT titration-CTC-mAECT 3. ED by 4
4. LNP-CTC-mAECT 4. €76
5. LNP-TBF-CTC-mAECT 5. €200
6. LNP-CTC-CATT titration 6. dominated by 5
7. LNP-TBF-CTC-mAECT-CATT
titration
7. €2,618
Politi, 1995
[16]
Treatment 1. None 1. - 1. - - -
2. Melarsoprol Melarsoprol 2. $8 2. $209
3. Melarsoprol DFMO 3. $41 3. $1,033
4. DFMO DFMO 4. $167 4. $4,444
Robays, 2008
[21]
Treatment - Donated drug costs
not included:
Donated drug costs
not included:
-
1. Melarsoprol 1. - 1. -
2. DFMO 2. $1596 2. $58
Donated drug costs
included:
Donated drug costs
included:
1. - 1. -
2.$8,169 2.$299
Lutumba,
2007 [20]
Case detection and diagnosis,
treatment
1. Treatment alone 1. - - - 1. -
2. Active screening + treatment 2.$17 2. $301
Shaw 1989
[15]
Case detection and diagnosis,
treatment, vector control
1. Find and Treat NA NA NA NA
2. Vector control (traps/targets +
ground spraying)
*compared to CATT alone. Abbreviations: ED, extendedly dominated; NA, not applicable as results not reported incrementally.
doi:10.1371/journal.pntd.0003397.t005
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literature. Strategies towards elimination should continue to consider the impact of these compo-
nents but also aim to highlight their individual and collective use within a formal strategy for
reaching elimination. This was highlighted in the study by Lutumba et al. [20] in which case-de-
tection with treatment was compared to treatment alone and also in the work by Shaw and col-
leagues in 1989 in which essentially all four categories were evaluated with varying incidence.
Within diagnostics, algorithms for CATT showed that the addition of tests led to more efficient
outcomes [19]. However, there is still a gap in cost-effectiveness knowledge of the current treat-
ment for HAT, NECT. As global investors, partners, and academic groups [10,11,25–29] are
now working together not only to control and treat this disease but also to develop novel diag-
nostic tools [9,11] and drug treatments [10], it would be useful to compare NECT to interven-
tions that have recently come or are near entry to the market (e.g., fexinidazole [10] and rapid
diagnostic tests [9,11]). Shaw et al. [15,17] and Lutumba [20] both made reference to the benefits
of combining interventions for treatment, and it would be wise for stakeholders to move beyond
this and develop more complicated and time-sensitive strategies with interventions not only on
their own but in combination to identify the most cost-effective pathways towards elimination.
There are still some additional considerations that have not been considered as components
in HAT economic evaluations. Although T. b. gambiense HAT contributes to 95% of the HAT
disease [5], separate strategies for T. b. rhodesiense could also be considered. Cultural beliefs
and attitudes towards HAT will also play a role in the effectiveness of interventions [30], and
although education and community sensitization programs for HAT have been evaluated in
terms of their societal benefit and impact on changing knowledge and behaviour [31–33], no
studies have shown their benefit in terms of cost-effectiveness. Methods of delivery and inte-
gration of health systems should also be further explored in terms of accessibility and availabili-
ty, as resource constraints and lack of access in remote areas may delay elimination timelines if
not considered beforehand [34,35].
Potential Use of Cost-Effective Modelling for HAT Control and
Elimination
It was quite evident from the literature review that modelling will play a role in the economic
evaluation of HAT. Most of the previous economic evaluations conducted were based on mod-
els, and modelling is known to assist with forecasting future economic consequences [13]. De-
cision makers would benefit from the use of whole disease modelling of alternative elimination
scenarios because it would allow them to consider the implications and incremental benefits of
each potential strategy. Previous economic evaluation studies reliant on modelling have ad-
dressed how individual interventions reduced transmission but not how these interventions, or
combinations of them, could lead to eventual elimination or interruption of disease transmis-
sion. Current modelling techniques for economic evaluation, including those used to evaluate
the impact of uncertainty related to model parameters, would also be useful for decision mak-
ers in communicating the consequences of choosing non-cost-effective strategies [36]. Addi-
tionally, modelling the feasibility of interventions through health service delivery is also
necessary. For example, the results from an economic evaluation regarding diagnostic algo-
rithms [19] showed that sometimes even the most cost-effective tools may not be affordable or
feasible in some of the locations where HAT occurs [19].
Potential Use of Economic Evaluation Methodology in HAT Control and
Elimination
A few considerations of cost-effective interventions could be gleaned from the few economic
evaluations found. This was highlighted in the scenario described by Lutumba et al. [20] in
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which case-detection with treatment was more cost-effective than treatment alone, and an eco-
nomic evaluation of diagnostic algorithms showed that the addition of tests to CATT could in-
crease cost-effectiveness [19]. Treatment regimens including melarsoprol and eflornithine
were considered cost-effective [16,21] for patients with HAT T. b. gambiense, and Politi’s anal-
ysis in 1995 also demonstrated a good understanding of economic outcomes because domi-
nance was assessed and the importance of the efficiency frontier was illustrated [16].
Dominance refers to the economic concept that an intervention that costs less and has better
outcomes relative to its comparator is considered dominant [13]. In regards to budgeting, sen-
sitivity analyses [15,17,18] demonstrated that prevalence is related to costs. This will be impor-
tant to consider because the cost per patient will increase towards the end goal of HAT
elimination, but the overall cost per benefit still needs to be ascertained.
The economic evaluations reviewed presented some methodological inconsistencies. For ex-
ample, there was a lack of clarity in reporting costs and consequences incrementally to a base-case
scenario or relative to the next-best intervention. Historically calculations may have been done
this way because of the “generalized cost-effectiveness”method [37], but if incremental and net
benefits are always compared to “do nothing” instead of to the next-best option available, then
the consequences of this methodology could lead to error [38]. Furthermore, when multiple strat-
egies are being considered, dominance needs to be examined. Although four out of seven studies
had more than two competing strategies, dominance was only addressed once. Evaluations that
ignore dominance could lead to decision errors in which the health utility is not maximised at a
societal level [13,39]. Cost-effectiveness was also referred to by the authors without making refer-
ence to a cost-effectiveness threshold. WHO-CHOICE [24] has defined thresholds previously;
however, it is not clear if these thresholds values are acceptable for all global stakeholders because
the authors did not always refer to a threshold value to determine cost-effectiveness.
The methodology of CEA with different interventions permits one to compare varying strat-
egies across a disease, but the outcomes need to be unified so that decision makers can assess
these comparators with ease and clarity. It is evident from this review that although CEA re-
search may be conducted, the results are hard to interpret without standardization or reporting
in a common metric (e.g., cost per DALY). Following existing guidelines for economic evalua-
tion such as the SIGN Guidelines [14] and the more recent Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) statement [40] or developing guidelines that stake-
holders feel acceptable for an elimination strategy would allow for consistency of analyses for
HAT and other neglected tropical diseases. Formal economic evaluation guidelines and even a
standard reference case have been developed by various public health funders [41–43], and re-
searchers should consider these standards to further the future of CEA within tropical disease
and disease elimination decision-making. In addition, traditional CEA measures two outcomes
(cost and effects), but programs for elimination also need to consider time. Health economists
will need to consider how to make recommendations to stakeholders for strategy prioritization
considering all three elements for elimination.
Conclusions
This review has demonstrated that previous research highlights the main components that play
a role in elimination. Furthermore, cost-effective modelling and economic evaluation have
been used and could address future economic concerns regarding elimination. Researchers in-
terested in evaluating economic concerns regarding HAT elimination should think about
modelling elimination strategies to assess cost-effectiveness using standardized methodology
in order to assist stakeholder and key funders. These analyses would be of use since HAT is
currently being prioritized as a NTD to reach elimination by 2020.
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Boxes
Box 1. Key Learning Points from Economic Evaluations for HAT
• Most interventions assessed to date to reduce and control HAT are fairly cost-effective.
• Previous publications have focused on case detection, diagnostics, drug treatments,
and vector control; however, examination of combinations of interventions have not
yet been assessed for HAT elimination.
• No studies to date have explored the CE of the current first-line treatment for stage
one HAT, NECT.
• The feasibility of deployment of current and new interventions for HAT also should be
taken into consideration in future economic evaluations.
• Previous economic evaluations demonstrate that this method can play a role in assess-
ing the cost-effectiveness of interventions for a disease in the developing world.
Box 2. Key Papers in Economic Evaluation of HAT Interventions
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